GoAI
Get started
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

PRQR

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.34

+$0.07 · +3.08%

Aug 21, 4:00 PM ET

PRQR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

49

Fair Value

Momentum

43

Neutral

Sentiment

61

Bullish

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.

Industry
Biotechnology
Sector
Healthcare
Headquarters
NL
CEO
Daniel Anton de Boer
Listed since
Sep 18, 2014
Employees
166

Market position

Day range

Current $2.34

52-week range

Current $2.34

Open
$2.32
Previous close
$2.27
Volume
725.82K
0.77× average
Average volume
947.42K
Average daily volume
Market cap
246.42M USD
Beta
0.03
Market reference 1
50-day average
$1.7954
+30.33% above average
200-day average
$1.7843
+31.14% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
88.99M EUR
P/E (TTM)
-5.07×
P/B (TTM)
2.78×
P/S (TTM)
11.37×
EV / EBITDA
-2.4×
Earnings yield
-22.37%
Free cash flow yield
-29.71%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
92.33%
Operating margin
-232.71%
Net margin
-228.29%
Return on equity
-69.88%
Return on assets
-30.60%
Return on invested capital
-42.35%

Financial health

Debt / equity
0.17×
Current ratio
3.09×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends565%-1295%-3155%-5015%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 83.01%Operating margin, FY2021: -4285.39%Operating margin, FY2022: -1812.99%Operating margin, FY2023: -489.09%Operating margin, FY2024: -161.18%Operating margin, FY2025: -275.91%Net margin, FY2021: -4549.81%Net margin, FY2022: -1792.54%Net margin, FY2023: -431.67%Net margin, FY2024: -146.86%Net margin, FY2025: -265.21%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 83.01%. Operating margin FY2021 -4285.39%. Operating margin FY2022 -1812.99%. Operating margin FY2023 -489.09%. Operating margin FY2024 -161.18%. Operating margin FY2025 -275.91%. Net margin FY2021 -4549.81%. Net margin FY2022 -1792.54%. Net margin FY2023 -431.67%. Net margin FY2024 -146.86%. Net margin FY2025 -265.21%.

Income trends

Revenue

15.28M EUR-19.18%

Operating income

−42.15M EUR-38.34%

Net income

−40.52M EUR-45.95%
Income trends across reported periods27.31M EUR−6.31M EUR−39.94M EUR−73.57M EURRevenue, FY2021: 1.34M EURRevenue, FY2022: 3.59M EURRevenue, FY2023: 6.51M EURRevenue, FY2024: 18.91M EURRevenue, FY2025: 15.28M EUROperating income, FY2021: −57.21M EUROperating income, FY2022: −65.16M EUROperating income, FY2023: −31.86M EUROperating income, FY2024: −30.47M EUROperating income, FY2025: −42.15M EURNet income, FY2021: −60.74M EURNet income, FY2022: −64.42M EURNet income, FY2023: −28.12M EURNet income, FY2024: −27.76M EURNet income, FY2025: −40.52M EURFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.34M EUR. Revenue FY2022 3.59M EUR. Revenue FY2023 6.51M EUR. Revenue FY2024 18.91M EUR. Revenue FY2025 15.28M EUR. Operating income FY2021 −57.21M EUR. Operating income FY2022 −65.16M EUR. Operating income FY2023 −31.86M EUR. Operating income FY2024 −30.47M EUR. Operating income FY2025 −42.15M EUR. Net income FY2021 −60.74M EUR. Net income FY2022 −64.42M EUR. Net income FY2023 −28.12M EUR. Net income FY2024 −27.76M EUR. Net income FY2025 −40.52M EUR.
Metric (EUR)FY2025FY2024FY2023FY2022FY2021
Revenue15.28M EUR18.91M EUR6.51M EUR3.59M EUR1.34M EUR
Cost of goods sold2.6M EUR————
Gross profit12.68M EUR18.91M EUR6.51M EUR3.59M EUR1.34M EUR
Research and development40.72M EUR36.36M EUR25.15M EUR50.87M EUR42.22M EUR
Selling, general, and administrative15.06M EUR13.66M EUR16.24M EUR18.65M EUR17.37M EUR
Operating expenses54.84M EUR49.38M EUR38.37M EUR68.75M EUR58.55M EUR
Interest income2.24M EUR3.25M EUR2.59M EUR106K EUR5K EUR
Interest expense866.4K EUR1.08M EUR1.2M EUR5.13M EUR3.41M EUR
Depreciation and amortization2.6M EUR2.76M EUR2.51M EUR2.52M EUR2.33M EUR
Operating income−42.15M EUR−30.47M EUR−31.86M EUR−65.16M EUR−57.21M EUR
Net income−40.52M EUR−27.76M EUR−28.12M EUR−64.42M EUR−60.74M EUR

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 4 misses, 3 met estimates
Average EPS surprise
-0.59%
11 comparable reports
Latest EPS result
-0.1
Estimate -0.13 · Beat by 23.23%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.07-0.11-0.15-0.19Q1 '25MetQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MetQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual -0.1, estimate -0.1, surprise 0.00%, Met estimate. Q2 2025, reported May 8, 2025: actual -0.11, estimate -0.09, surprise -22.22%, Miss. Q3 2025, reported Aug 7, 2025: actual -0.14, estimate -0.08, surprise -75.00%, Miss. Q4 2025, reported Nov 6, 2025: actual -0.12, estimate -0.1, surprise -20.00%, Miss. Q1 2026, reported Mar 12, 2026: actual -0.09, estimate -0.08, surprise -12.50%, Miss. Q2 2026, reported May 12, 2026: actual -0.15, estimate -0.15, surprise 0.00%, Met estimate. Q3 2026, reported Aug 13, 2026: actual -0.1, estimate -0.13, surprise +23.23%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.11, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates10.62M7.74M4.87M2MQ1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 13, 2025: actual 4.46M USD, estimate 5.45M USD, surprise -18.10%, Miss. Q2 2025, reported May 8, 2025: actual 4.95M USD, estimate 4.8M USD, surprise +3.10%, Beat. Q3 2025, reported Aug 7, 2025: actual 4.49M USD, estimate 5.49M USD, surprise -18.16%, Miss. Q4 2025, reported Nov 6, 2025: actual 3.41M USD, estimate 6.12M USD, surprise -44.20%, Miss. Q1 2026, reported Mar 12, 2026: actual 5.54M USD, estimate 6.63M USD, surprise -16.41%, Miss. Q2 2026, reported May 12, 2026: actual 2.35M USD, estimate 5.19M USD, surprise -54.73%, Miss. Q3 2026, reported Aug 13, 2026: actual 10M USD, estimate 4.56M USD, surprise +119.32%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 3.87M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$3.00

28.21% upside
Past 12 months12-month forecastHigh $3.00Average $3.00Low $3.00

Rating distribution

12 ratings
Strong buy18%
Buy1083%
Hold18%
Sell00%
Strong sell00%

Recent analyst actions

10 institutions
Evercore ISI GroupmaintainOutperform
Jones TradingmaintainBuy
Cantor FitzgeraldmaintainOverweight
OppenheimermaintainOutperform

PRQR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research PRQR

research.disclaimer